Clearmind Medicine (NASDAQ:CMND) Releases Earnings Results

Clearmind Medicine (NASDAQ:CMND) issued its quarterly earnings data on Monday. The company reported ($6.78) earnings per share for the quarter, Zacks reports.

Clearmind Medicine Stock Up 0.9%

Shares of Clearmind Medicine stock opened at $3.37 on Tuesday. The firm has a market cap of $3.44 million, a price-to-earnings ratio of -0.02 and a beta of 0.65. The business has a fifty day simple moving average of $6.07 and a 200-day simple moving average of $16.05. Clearmind Medicine has a fifty-two week low of $2.10 and a fifty-two week high of $524.00.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research note on Saturday, May 23rd.

Insider Transactions at Clearmind Medicine

In other news, major shareholder Financial Lp Hrt bought 2,159,052 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average cost of $0.15 per share, with a total value of $323,857.80. Following the completion of the acquisition, the insider directly owned 2,063,266 shares in the company, valued at approximately $309,489.90. The trade was a -2,254.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.